Primary objective:~To evaluate the impact of metabolic disease on the progression of chronic hepatitis B~To observe HBsAg/HBeAg/HBV DNA changes /HBsAg seroconversion~To determine high rates of Liver Cirrhosis and Hepatocellular Carcinoma~Group 1 : CHB with diabetes Group 2 : CHB with hyperlipemia Group 3 : CHB without metabolic diseases~Study Duration (in months) 24 months
HBV(hepatitis B virus) with metabolic comorbidities may accelerate liver disease progression and increase the risk of HCC(Hepatocellular Carcinoma)development. It is reported combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone. Consequently, hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indications.